These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12115169)

  • 1. Comment on prescribing tumor necrosis factor inhibitors.
    Hanauer LB
    Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al.
    Olivieri I; Padula A; Scarano E
    Arthritis Rheum; 2002 Dec; 46(12):3396-8; author reply 3398. PubMed ID: 12483753
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of tumor necrosis factor inhibitors in patients with RA.
    Trethewey P
    JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
    [No Abstract]   [Full Text] [Related]  

  • 5. Do rheumatology cost-effectiveness analyses make sense?
    Wolfe F; Michaud K; Pincus T
    Rheumatology (Oxford); 2004 Jan; 43(1):4-6. PubMed ID: 14523227
    [No Abstract]   [Full Text] [Related]  

  • 6. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 8. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
    Lehnen M; Goos M; Dissemond J
    Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
    [No Abstract]   [Full Text] [Related]  

  • 9. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.
    Wagner AD; Andresen J; Jendro MC; Hülsemann JL; Zeidler H
    Arthritis Rheum; 2002 Jul; 46(7):1965-8. PubMed ID: 12124882
    [No Abstract]   [Full Text] [Related]  

  • 10. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriatic onychopachydermoperiostitis: improvement with etanercept.
    Dans M; Hivnor C; van Voorhees AS
    Br J Dermatol; 2005 Oct; 153(4):858-9. PubMed ID: 16181482
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic viral hepatitis and TNF-alpha blockade.
    Raftery G; Griffiths B; Kay L; Kane D
    Rheumatology (Oxford); 2007 Aug; 46(8):1381; author reply 1381-2. PubMed ID: 17567635
    [No Abstract]   [Full Text] [Related]  

  • 16. Taiwan experience with etanercept in juvenile rheumatoid arthritis.
    Lai JH
    J Microbiol Immunol Infect; 2005 Dec; 38(6):451-4. PubMed ID: 16341348
    [No Abstract]   [Full Text] [Related]  

  • 17. Can tumor necrosis factor alpha blockade predispose to severe babesiosis?
    Taiwo B; Lee C; Venkat D; Tambar S; Sutton SH
    Arthritis Rheum; 2007 Feb; 57(1):179-81. PubMed ID: 17266091
    [No Abstract]   [Full Text] [Related]  

  • 18. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 19. Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.
    Sheehy C; Murphy E; Barry M
    Rheumatology (Oxford); 2006 Oct; 45(10):1314-5. PubMed ID: 16837474
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful etanercept treatment of constrictive pericarditis complicating rheumatoid arthritis.
    Aslangul E; Perrot S; Durand E; Mousseaux E; Le Jeunne C; Capron L
    Rheumatology (Oxford); 2005 Dec; 44(12):1581-3. PubMed ID: 16204377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.